161 related articles for article (PubMed ID: 19748743)
21. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
Noah BA; Brushwood DB
J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
Manchikanti L; Singh A
Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
[TBL] [Abstract][Full Text] [Related]
23. Abuse of prescription drugs and the risk of addiction.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S4-7. PubMed ID: 16563663
[TBL] [Abstract][Full Text] [Related]
24. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
[TBL] [Abstract][Full Text] [Related]
25. What's the problem with generic antiepileptic drugs?: a call to action.
Berg MJ
Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
[No Abstract] [Full Text] [Related]
26. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
27. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future.
Loder E
Cephalalgia; 2006 Feb; 26(2):89-97. PubMed ID: 16426261
[TBL] [Abstract][Full Text] [Related]
28. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
[TBL] [Abstract][Full Text] [Related]
29. Risk identification, risk assessment, and risk management of abusable drug formulations.
Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
[TBL] [Abstract][Full Text] [Related]
30. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
31. Automated support for pharmacovigilance: a proposed system.
Bright RA; Nelson RC
Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
[TBL] [Abstract][Full Text] [Related]
32. The burden of the nonmedical use of prescription opioid analgesics.
Gilson AM; Kreis PG
Pain Med; 2009 Jul; 10 Suppl 2():S89-100. PubMed ID: 19691688
[TBL] [Abstract][Full Text] [Related]
33. The nonmedical use of prescription drugs by adolescents.
Rogers PD; Copley L
Adolesc Med State Art Rev; 2009 Apr; 20(1):1-8, vii. PubMed ID: 19492687
[TBL] [Abstract][Full Text] [Related]
34. Formulation considerations for the development of medications with abuse potential.
Mansbach RS; Moore RA
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
[TBL] [Abstract][Full Text] [Related]
35. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
Mathis LL; Iyasu S
Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
[TBL] [Abstract][Full Text] [Related]
36. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
37. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
Alder HC
Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
[TBL] [Abstract][Full Text] [Related]
38. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
39. [Adverse events related to substitution of generic products in Norway 2005].
Reppe LA; Stenberg-Nilsen H; Harg P; Hegge AB; Lillefloth AK; Buajordet I
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2696-700. PubMed ID: 19079413
[TBL] [Abstract][Full Text] [Related]
40. Post-marketing surveillance of licensed medicinal and other products.
Griffin JP
Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
